Anastrozole Tablet, Film Coated
Product Images NDC 0093-7536

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 0093-7536). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Anastrozole Tablets Usp A078058 1

Chemical structure of Anastrozole, showing its molecular arrangement with a triazole ring connected to a benzene ring substituted with cyano and methyl groups.*

FDA Label Image

Anastrozole Tablets Usp A078058 2

A line chart comparing disease-free survival over time (in months) between two randomized treatment groups: anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, ranging from 0.0 to 1.0, and the x-axis shows disease-free survival in months up to 96. Two lines depict survival trends for each treatment group over this period.*

FDA Label Image

Anastrozole Tablets Usp A078058 3

A line graph showing disease-free survival over time in months, comparing the proportion of patients alive and disease-free for two treatments: anastrozole (dashed line) and tamoxifen (solid line). The chart plots survival proportion decreasing from 1.0 to about 0.8 over approximately 90 months.*

FDA Label Image

Anastrozole Tablets Usp A078058 4

A Kaplan-Meier survival curve chart comparing the proportion event free over time in months between Anastrozole and Tamoxifen treatment groups. The chart includes a table showing the number of patients at risk at multiple time points up to 120 months for each treatment group.*

FDA Label Image

Anastrozole Tablets Usp A078058 5

A Kaplan-Meier survival curve chart showing the proportion of patients event-free over time in months for two treatment groups: Anastrozole and Tamoxifen. The horizontal axis represents time to event (months) up to 120 months, and the vertical axis represents the proportion event-free. A table below the graph shows the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Anastrozole Tablets Usp A078058 6

A Kaplan-Meier survival curve chart showing the proportion of patients without progression over time (in months) for two treatments, Anastrozole and Tamoxifen, in a randomized treatment study. The vertical axis represents the proportion not progressing, while the horizontal axis shows time to progression in months. Anastrozole is represented by a solid line and Tamoxifen by a dashed line.*

FDA Label Image

Anastrozole Tablets Usp A078058 7

A Kaplan-Meier survival curve chart comparing the proportion of patients not progressing (y-axis) over time in months (x-axis) between two randomized treatments: Anastrozole and Tamoxifen. The chart includes a table below indicating the number of patients at risk at various time points up to 42 months.*

FDA Label Image

Anastrozole Tablets Usp A078058 8

Anastrozole Tablets USP 1 mg film-coated tablet label by Teva Pharmaceuticals USA, Inc. The label includes the NDC 0093-7536, storage instructions, manufacturer information from Israel, a barcode, and a pink serialization coding area. The label specifies the product as prescription-only with a count of 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.